Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Conference Conversations: Pharmacist Perspectives From IAS 2021

July 18-21, 2021; Virtual
Hear insights from Jennifer Cocohoba, PharmD, and Jason Schafer, PharmD, MPH, on exciting new data from IAS 2021, including 2-drug regimens for ART, long-acting ART, and novel antiretrovirals, and learn how these new data influence the role of the pharmacist in caring for patients with HIV.
Jennifer Cocohoba Headshot
Jennifer Cocohoba, PharmD
person default
Jason Schafer, PharmD, MPH
Released: August 23, 2021

In this episode, Jennifer Cocohoba, PharmD, and Jason Schafer, PharmD, MPH, discuss key studies from IAS 2021 that will influence the role of the pharmacist in the treatment and prevention of HIV. Their discussion includes analyses of:

  • The 144-week analysis of the TANGO study, showing high rates of virologic suppression of patients switched from a TAF-containing regimen to DTG plus 3TC
  • The SALSA study, a noninferiority study evaluating sustained virologic suppression in patients switched from a 3- or 4-drug regimen to DTG plus 3TC
  • An extension of the FLAIR study, evaluating efficacy and safety of long-acting CAB plus RPV in treatment-naive patients
  • The CUSTOMIZE study, an implementation effectiveness study that evaluated the feasibility of implementing provision of long-acting CAB plus RPV in the clinic setting
  • The HPTN 084 study of PrEP using CAB vs TDF plus FTC in sexually active cisgender women
  • The CALIBRATE and CAPELLA studies of long-acting lenacapavir in treatment-naive and treatment-experienced patients, respectively

Information on this Educational Activity

Faculty

Jennifer Cocohoba, PharmD

Professor
Department of Clinical Pharmacy
University of California, San Francisco
Pharmacist
Women's HIV Program
University of California San Francisco Medical Center
San Francisco, California

Jennifer Cocohoba, PharmD, has disclosed that she has received funds for research support from ViiV Healthcare.
Jason Schafer, PharmD, MPH

Professor and Vice Chair
Jefferson College of Pharmacy
Thomas Jefferson University
Philadelphia, Pennsylvania

Jason Schafer, MD, MPH, has disclosed that he has received funds for research support from Gilead Sciences and Merck and consulting fees from Merck and ViiV.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

Dr. Samantha Strong shares key data and recommendations to consider when choosing a PrEP option for a cisgender woman, from Clinical Care Options (CCO)

Samantha Strong, PharmD, BCACP, AAHIVP, CDCES Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: October 6, 2022 Expired: October 5, 2023

Expert insights on ART management, guideline updates, and resistance analysis, from Dr Eric S. Daar and Clinical Care Options (CCO)

Eric S. Daar, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Pharmacists: 1.0 contact hour (0.1 CEUs) Released: October 6, 2022 Expired: October 5, 2023

Clinical Care Options (CCO) slideset providing expert insights for ART management in complex clinical situations, including extensive previous treatment

Joseph J. Eron, Jr., MD
Program Director
Jeffrey Kwong, DNP, MPH, FAANP, FAAN
Program Director
Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director
Eric S. Daar, MD
Released: October 6, 2022

Slides on ART management, guideline updates, and resistance analysis, from Dr Eric S. Daar and Clinical Care Options (CCO)

Eric S. Daar, MD Released: October 5, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings